Grufity logoGrufity logo

Baxter International Inc Stock Research

BAX

38.37USD+0.14(+0.37%)Market Closed

Market Summary

USD38.37+0.14
Market Closed
0.37%

BAX Alerts

BAX Stock Price

BAX RSI Chart

BAX Valuation

Market Cap

19.3B

Price/Earnings (Trailing)

-7.95

Price/Sales (Trailing)

1.28

EV/EBITDA

-25.11

Price/Free Cashflow

15.97

BAX Price/Sales (Trailing)

BAX Profitability

EBT Margin

-15.57%

Return on Equity

-41.71%

Return on Assets

-8.6%

Free Cashflow Yield

6.26%

BAX Fundamentals

BAX Revenue

Revenue (TTM)

15.1B

Revenue Y/Y

10.61%

Revenue Q/Q

3.02%

BAX Earnings

Earnings (TTM)

-2.4B

Earnings Y/Y

-23.95%

Earnings Q/Q

106.16%

Price Action

52 Week Range

37.7480.41
(Low)(High)

Last 7 days

-3.1%

Last 30 days

-5.6%

Last 90 days

-24.7%

Trailing 12 Months

-51.2%

BAX Financial Health

Current Ratio

1.69

Debt/Equity

2.77

Debt/Cashflow

0.07

BAX Investor Care

Dividend Yield

2.07%

Dividend/Share (TTM)

1.14

Shares Dilution (1Y)

0.80%

Diluted EPS (TTM)

-4.83

Peers (Alternatives to Baxter International)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
SYK
104.1B
18.4B
 2.26% 8.00%
44.16
5.64
 7.84% 18.25%
ISRG
84.2B
6.2B
 -4.47% -13.27%
63.66
13.53
 8.97% -22.43%
BSX
69.1B
12.7B
 0.59% 12.45%
99.06
5.45
 6.68% -32.95%
BDX
67.4B
19.0B
 -5.16% -6.78%
41.86
3.55
 -0.43% -8.78%
EW
49.8B
5.4B
 2.41% -25.12%
32.74
9.26
 2.86% 1.25%
MID-CAP
SWAV
7.2T
489.7M
 9.34% 31.15%
82.2K
16.8K
 106.51% 2464.23%
PEN
10.2B
847.1M
 -3.64% 34.52%
-5.1K
12.05
 13.32% -137.89%
GMED
5.2B
1.0B
 -11.64% -20.31%
30.19
5.09
 6.76% 24.45%
IRTC
3.5B
410.9M
 4.51% -3.13%
-29.82
8.43
 27.29% -14.60%
TNDM
2.7B
801.2M
 1.13% -58.87%
-28.25
3.34
 14.00% -707.69%
SMALL-CAP
SILK
1.7B
138.6M
 -15.68% 29.18%
-30.43
12.07
 36.62% -10.44%
ATEC
1.6B
350.9M
 10.38% 49.06%
-10.84
4.7
 44.26% -5.42%
AVNS
1.3B
820.0M
 -8.35% -12.22%
25.89
1.59
 10.13% 701.59%
CSII
828.4M
239.8M
 0.30% 1.49%
-21.88
3.45
 -4.74% -31.15%

Financials for Baxter International

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue2.5%15,11314,74014,19313,54512,784
Gross Profit1.1%5,3975,3405,5285,3085,105
  S&GA Expenses0.7%3,8873,8603,5933,2922,867
  R&D Expenses2.9%605588565556534
EBITDA-1.0%-1,345-1,3322,0112,030-
EBITDA Margin1.5%-0.09*-0.09*0.14*0.15*-
Earnings Before Taxes-2.6%-2,353-2,2941,1231,2201,477
EBT Margin0.0%-0.16*-0.16*0.08*0.09*-
Interest Expenses-12.2%-395-352-298-243-192
Net Income-2.4%-2,433-2,3761,0111,0571,284
Net Income Margin0.1%-0.16*-0.16*0.07*0.08*-
Free Cahsflow-17.3%1,2111,4651,8502,053-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.2%28,28727,96531,83132,71633,521
  Current Assets2.6%8,0117,8107,8828,1738,872
    Cash Equivalents7.3%1,7181,6011,8522,2942,951
  Inventory1.6%2,7182,6752,6632,5482,453
  Net PPE-3.6%4,7994,9765,1145,178-
  Goodwill3.1%6,8436,6399,6449,8169,836
Liabilities0.0%22,39222,38622,92823,59724,400
  Current Liabilities28.0%4,7453,7083,9163,8904,236
.    Short Term Borrowings8.7%299275200200301
  Long Term Debt-5.8%16,15317,149---
Shareholder's Equity5.4%5,8335,5358,9039,1199,077
  Retained Earnings0.2%14,05014,01517,09916,99417,065
  Additional Paid-In Capital0.4%6,3226,2976,2536,2076,197
Accumulated Depreciation-3.7%6,2856,5286,6436,550-
Shares Outstanding0%504504503--
Minority Interest40.9%62.0044.0044.0044.0044.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-17.3%1,2111,4651,8502,0532,222
  Share Based Compensation-12.0%154175164156146
Cashflow From Investing91.5%-931-10,942-10,965-10,966-11,200
Cashflow From Financing-118.1%-1,4387,9577,9358,0558,245
  Dividend Payments1.1%573567562545530
  Buy Backs0%32.0032.0035.00347600

Risks for BAX

What is the probability of a big loss on BAX?

32.7%

Probability that Baxter International stock will be more than 20% underwater in next one year

13.1%

Probability that Baxter International stock will be more than 30% underwater in next one year.

7.7%

Probability that Baxter International stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Baxter International was unfortunately bought at previous high price.

Drawdowns

Returns for BAX

Cumulative Returns on BAX

1.6%

10-Year Cumulative Returns

0.4%

7-Year Cumulative Returns

-9.9%

5-Year Cumulative Returns

-21.4%

3-Year Cumulative Returns

What are the long-term rolling returns for BAX?

FIve years rolling returns for Baxter International.

Annualized Returns

Which funds bought or sold BAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
reduced
-17.2
-90,575
334,425
 0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
2.77
-2,022,390
71,739,600
 0.08%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
added
2.16
-28,682
844,318
 0.32%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-0.93
-106,000
1,602,000
 0.01%
2023-03-03
TIAA, FSB
reduced
-4.23
-101,806
990,194
 -%
2023-03-02
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
new
-
104,743
104,743
 -%
2023-03-02
OLIVER LAGORE VANVALIN INVESTMENT GROUP
unchanged
-
-1,464
25,536
 0.01%
2023-03-01
WHITENER CAPITAL MANAGEMENT, INC.
added
0.59
-43,406
874,594
 0.38%
2023-03-01
PANORAMIC INVESTMENT ADVISORS, LLC
new
-
328,094
328,094
 0.34%
2023-02-28
Voya Investment Management LLC
reduced
-5.15
-1,801,890
15,793,100
 0.02%

1–10 of 48

Latest Funds Activity

Are funds buying BAX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BAX
No. of Funds

BAX Alerts

Baxter International News

Defense World

JDM Financial Group LLC Buys Shares of 1645 Baxter International ....

Defense World,
51 minutes ago

MarketWatch

West Pharmaceutical Services Inc. stock underperforms Wednesday when compared to competitors.

MarketWatch,
11 hours ago

MarketBeat

Baxter International Inc. (NYSE:BAX) Position Lessened by Beese ....

MarketBeat,
18 hours ago

InvestorsObserver

Baxter International Inc (BAX) is lower by 1.16% Wednesday In Premarket Trading.

InvestorsObserver,
21 hours ago

Nasdaq

Guru Fundamental Report for BAX.

Nasdaq,
39 hours ago

Investing.com

Exclusive-Thermo Fisher, Celltrion vie for Baxter's biopharma unit ....

Investing.com,
41 hours ago

The News Heater

Baxter International Inc. (BAX) Shares Up Despite Recent Market ....

The News Heater,
2 days ago

DailyWealth

How the Silicon Valley 'Bailout' Saved the Mortgage Market ....

DailyWealth,
2 days ago

MarketBeat

1972243 Shares in Baxter International Inc. (NYSE:BAX) Acquired ....

MarketBeat,
3 days ago

MarketBeat

California State Teachers Retirement System Lowers Holdings in ....

MarketBeat,
5 days ago

MarketWatch

West Pharmaceutical Services Inc. stock outperforms competitors despite losses on the day.

MarketWatch,
5 days ago

Defense World

Teachers Retirement System of The State of Kentucky Takes ....

Defense World,
6 days ago

MarketBeat

UBS Asset Management Americas Inc. Acquires 103076 Shares of ....

MarketBeat,
12 days ago

Best Stocks

Analysts have given Baxter International Inc. (NYSE:BAX) a ....

Best Stocks,
12 days ago

Best Stocks

Baxter Issues Urgent Medical Device Correction for Life2000 ....

Best Stocks,
13 days ago

Nasdaq

April 28th Options Now Available For Baxter International (BAX).

Nasdaq,
14 days ago

Schedule 13G FIlings of Baxter International

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.86%
49,705,350
SC 13G/A
Feb 08, 2023
morgan stanley
5.5%
27,835,167
SC 13G/A
Feb 06, 2023
wellington management group llp
7.16%
36,104,233
SC 13G/A
Jan 06, 2023
blackrock inc.
10.0%
50,522,292
SC 13G/A
Mar 10, 2022
wellington management group llp
11.33%
56,894,500
SC 13G/A
Feb 09, 2022
morgan stanley
5.7%
28,501,661
SC 13G
Feb 09, 2022
vanguard group inc
7.79%
38,980,284
SC 13G/A
Feb 04, 2022
wellington management group llp
9.91%
49,623,775
SC 13G/A
Feb 01, 2022
blackrock inc.
8.0%
40,110,136
SC 13G/A
Apr 12, 2021
wellington management group llp
10.11%
51,116,416
SC 13G/A

BAX Fair Value

Baxter International fair value in different scenarios

The table shows the Fair Value estimates for Baxter International for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

31.03

-19.13%

36.70

-4.35%

52.54

36.93%

63.63

65.83%

75.19

95.96%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Baxter International Fair Value Estimates

Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Baxter International

View All Filings
Date Filed Form Type Document
Mar 13, 2023
8-K
Current Report
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading
Mar 06, 2023
4
Insider Trading

Latest Insider Trading transactions for BAX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-03
Rasul Reaz
sold (taxes)
-5,911
39.94
-148
evp, group pres, healthcare
2023-03-03
Knight Heather
sold (taxes)
-8,786
39.94
-220
evp, group pres, medical
2023-03-03
Stevens Brian
sold (taxes)
-7,348
39.94
-184
svp, cao and controller
2023-03-02
Rasul Reaz
sold (taxes)
-16,481
39.62
-416
evp, group pres, healthcare
2023-03-02
ALMEIDA JOSE E
sold (taxes)
-183,916
39.62
-4,642
chairman, ceo and president
2023-03-02
SACCARO JAMES
sold (taxes)
-42,036
39.62
-1,061
evp, chief financial officer
2023-03-02
Mason Jeanne K
sold (taxes)
-18,225
39.62
-460
svp, human resources
2023-03-02
Franzi Cristiano
sold (taxes)
-5,784
39.62
-146
svp, president, emea
2023-03-02
Kunzler Jacqueline
sold (taxes)
-10,737
39.62
-271
svp, chief quality officer
2023-03-02
Borzi James W
sold (taxes)
-18,779
39.62
-474
svp, global supply chain

1–10 of 50

About Baxter International

José E. Almeida
www.baxter.com
60000
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

BAX Income Statement

2022-09-30
Condensed Consolidated Statements of Income (Loss) (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net sales$ 3,773$ 3,226$ 11,226$ 9,270
Cost of sales2,6401,9057,2925,571
Gross margin1,1331,3213,9343,699
Selling, general and administrative expenses9476802,9751,982
Research and development expenses152129450396
Goodwill impairments2,78502,7850
Other operating expense (income), net48(1)20(6)
Operating income (loss)(2,799)513(2,296)1,327
Interest expense, net10450278118
Other (income) expense, net6312315
Income (loss) before income taxes(2,966)451(2,577)1,194
Income tax expense (benefit)(32)(1)29141
Net income (loss)(2,934)452(2,606)1,053
Net income attributable to noncontrolling interests3287
Net income (loss) attributable to Baxter stockholders$ (2,937)$ 450$ (2,614)$ 1,046
Earnings (loss) per share    
Basic (in dollars per share)$ (5.83)$ 0.90$ (5.20)$ 2.08
Diluted (in dollars per share)$ (5.83)$ 0.89$ (5.20)$ 2.06
Weighted-average number of shares outstanding    
Basic (in shares)504500503503
Diluted (in shares)504506503509

BAX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,601$ 2,951
Accounts receivable, net of allowances of $120 in 2022 and $122 in 20212,5552,629
Inventories2,6752,453
Prepaid expenses and other current assets979839
Total current assets7,8108,872
Property, plant and equipment, net4,7995,178
Goodwill6,6399,836
Other intangible assets, net6,9277,792
Operating lease right-of-use assets546630
Other non-current assets1,2441,213
Total assets27,96533,521
Current liabilities:  
Short-term debt275301
Current maturities of long-term debt and finance lease obligations4210
Accounts payable1,2341,246
Accrued expenses and other current liabilities2,1952,479
Total current liabilities3,7084,236
Long-term debt and finance lease obligations, less current portion16,15317,149
Operating lease liabilities454522
Other non-current liabilities2,0712,493
Total liabilities22,38624,400
Commitments and contingencies
Equity:  
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2022 and 2021683683
Common stock in treasury, at cost,179,451,293 shares in 2022 and 181,879,516 shares in 2021(11,406)(11,488)
Additional contributed capital6,2976,197
Retained earnings14,01517,065
Accumulated other comprehensive income (loss)(4,054)(3,380)
Total Baxter stockholders’ equity5,5359,077
Noncontrolling interests4444
Total equity5,5799,121
Total liabilities and equity$ 27,965$ 33,521